非布司他联合氢氯噻嗪治疗慢性肾脏病的临床疗效

Clinical efficacy of febuxostat combined with hydrochlorothiazide in the treatment of chronic kidney disease

目的探讨慢性肾脏病患者联合应用非布司他、氢氯噻嗪治疗的临床效果。方法120例慢性肾脏病患者为研究对象,按随机数字表法分为观察组及对照组,各60例。对照组患者应用氢氯噻嗪单独治疗,观察组行氢氯噻嗪联合非布司他治疗。比较两组治疗效果、不良反应发生率及治疗前后血清胱抑素C(Cys-C)、N末端脑钠肽前体(NT-proBNP)、肾功能[尿素氮(BUN)、血肌酐(SCr)、尿蛋白(Upro)]改善情况。结果观察组治疗总有效率96.67%高于对照组的83.33%(P<0.05)。治疗前两组Cys-C和NT-proBNP水平均无显著差异(P>0.05);治疗后两组Cys-C和NT-proBNP水平均较治疗前降低,且观察组Cys-C(1.20±0.15)mg/L和NT-proBNP(1142.38±26.75)pg/ml均低于对照组的(1.52±0.29)mg/L、(1429.38±31.36)pg/ml(P<0.05)。治疗前两组BUN、SCr、Upro水平均无显著差异(P>0.05);治疗后两组BUN、SCr、Upro水平均降低,且观察组BUN(8.48±2.15)mmol/L、SCr(117.25±25.64)μmol/L、Upro(1.30±0.52)g/24 h低于对照组的(10.52±1.30)mmol/L、(153.19±41.43)μmol/L、(1.88±0.40)g/24 h(P<0.05)。观察组不良反应发生率3.33%低于对照组的16.67%(P<0.05)。结论慢性肾脏病患者应用非布司他联合氢氯噻嗪治疗的临床效果显著,不仅可改善患者Cys-C和NT-proBNP水平,而且可改善肾功能,且安全性较高,可促进患者病情康复。

Objective To explore the clinical effect of febuxostat combined with hydrochlorothiazide in the treatment of chronic kidney disease.Methods 120 patients with chronic kidney disease were selected as the subjects of this study.They were divided into the observation group and the control group according to the random numerical table,with 60 cases in each group.The patients in the control group were treated with hydrochlorothiazide alone,and the patients in the observation group were treated with hydrochlorothiazide combined with febuxostat.Comparison was made on treatment effect,incidence of adverse reactions,serum cystatin C(Cys-C),and N-terminal pro brain natriuretic peptide(NT-proBNP),renal function[blood urea nitrogen(BUN),serum creatinine(SCr),urinary protein(Upro)]between the two groups.Results The total effective rate of the observation group was 96.67%,which was higher than 83.33%of the control group(P<0.05).Before treatment,there were no significant differences in the levels of Cys-C and NT-proBNP between the two groups(P>0.05).After treatment,the levels of Cys-C and NT-proBNP in both groups were lower than those before treatment;the observation group had Cys-C of(1.20±0.15)mg/L and NT-proBNP of(1142.38±26.75)pg/ml,which were lower than(1.52±0.29)mg/L and(1429.38±31.36)pg/ml in the control group(P<0.05).Before treatment,there were no significant differences in BUN,SCr and Upro levels between the two groups(P>0.05).After treatment,BUN,SCr and Upro levels decreased in both groups;the observation group had BUN of(8.48±2.15)mmol/L,SCr of(117.25±25.64)μmol/L,and Upro of(1.30±0.52)g/24 h,which were lower than(10.52±1.30)mmol/L,(153.19±41.43)μmol/L,and(1.88±0.40)g/24 h in the control group(P<0.05).The incidence of adverse reactions in the observation group was 3.33%,which was lower than 16.67%in the control group(P<0.05).Conclusion The clinical effect of febuxostat combined with hydrochlorothiazide in the treatment of chronic kidney disease patients is significant.It can not only improve the levels of Cys-C and NT proBNP,but also improve the renal function of patients with high safety and promote the recovery of patients.